Arrowhead Research Corp (ARWR) 6.77 $ARWR
Today's Review on Biotech Equities - Vertex Pharma, Alexion Pharma, Arrowhead Research, Medivation, and Incyte
PR Newswire - Tue Feb 10, 8:10AM CST
Editor Note: For more information about this release, please scroll to bottom.
MDVN: 104.71 (+0.67), VRTX: 113.66 (+4.03), ARWR: 6.77 (+0.21), INCY: 75.94 (+0.28), ALXN: 182.29 (+6.02)
Arrowhead Research Corporation's (ARWR) CEO Chris Anzalone on Q1 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Feb 09, 9:59PM CST
ARWR: 6.77 (+0.21)
Arrowhead Research (ARWR) Q1 2015 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Mon Feb 09, 3:25PM CST
ARWR: 6.77 (+0.21)
Arrowhead Research reports 1Q loss
Automated Insights - Mon Feb 09, 3:12PM CST
PASADENA, Calif. (AP) _ Arrowhead Research Corp. (ARWR) on Monday reported a loss of $22.6 million in its fiscal first quarter.
ARWR: 6.77 (+0.21)
Arrowhead Research Corporation misses by $0.07
Seeking Alpha - at Seeking Alpha - Mon Feb 09, 3:03PM CST
ARWR: 6.77 (+0.21)
Arrowhead Reports Fiscal 2015 First Quarter Financial Results
Business Wire - Mon Feb 09, 3:01PM CST
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced financial results for its fiscal 2015 first quarter ended December 31, 2014. The company is hosting a conference call at 4:30 p.m. EST to discuss results.
ARWR: 6.77 (+0.21)
Earnings Peek: Arrowhead Research Corporation's Focus Is On The Clinical Hold
Clinically Sound Investor - at Seeking Alpha - Wed Feb 04, 8:42AM CST
ARWR: 6.77 (+0.21)
Why Arrowhead Research Corp. Shares Plunged 14% in January
Sean Williams, The Motley Fool - Motley Fool - Mon Feb 02, 4:40PM CST
ARWR data by YCharts What: Shares of Arrowhead Research , a clinical-stage biopharmaceutical company focused on treating serious diseases through RNA-therapeutics, plunged 14% in January based on data from S&P Capital IQ following an...
ARWR: 6.77 (+0.21)
Arrowhead Research reports February 9
Seeking Alpha - at Seeking Alpha - Mon Feb 02, 3:15PM CST
ARWR: 6.77 (+0.21)
Arrowhead to Report Fiscal 2015 First Quarter Financial Results
Business Wire - Mon Feb 02, 3:01PM CST
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it will report its financial results for the fiscal 2015 first quarter ended December 31, 2014, on Monday, February 9, 2015, at 4:30 p.m. EST. To participate in the conference call, please dial 855-215-6159 (toll free from the US) or 315-625-6887 (for international callers) and enter Conference ID 76024600. Investors may also access a live audio webcast of this conference call on the Company's website at http://ir.arrowheadresearch.com/events.cfm.
ARWR: 6.77 (+0.21)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Jan 22, 8:15AM CST
ARWR: 6.77 (+0.21), BBRY: 10.09 (+0.23), NADL: 2.10 (-0.02), FXCM: 2.21 (-0.01), CYN: 90.32 (+0.49), PBR: 6.98 (+0.44), XLNX: 41.51 (+0.51), NERV: 4.68 (+0.09), FWM: 5.55 (+0.08), CYTR: 2.96 (+0.23), FFIV: 116.64 (+1.37), LOGI: 14.86 (-0.02), LE: 35.84 (+0.19), SNDK: 82.81 (+0.51)
Downgrade Alert for Arrowhead Research (ARWR)
Comtex SmarTrend(R) - Thu Jan 22, 7:17AM CST
Arrowhead Research (NASDAQ:ARWR) was downgraded from Buy to Hold at Deutsche Bank today. The stock closed yesterday at $6.76 on volume of 1.8 million shares, below average daily volume of 3.2 million. There is potential upside of 162.6% for shares of Arrowhead Research based on a current price of $6.76 and an average consensus analyst price target of $17.75. The stock should hit resistance at its 200-day moving average (MA) of $10.80, as well as support at its 50-day MA of $6.31.
ARWR: 6.77 (+0.21)
Seeking Alpha's Biotech Weekly: Roche Takes Control, Shire's A Buyer, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Jan 16, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
ZIOP: 9.64 (-0.35), ARWR: 6.77 (+0.21), XON: 39.30 (+1.05), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), MNKD: 7.00 (+0.02), RGDO: 1.17 (+0.02), HUM: 152.67 (-1.06), ETRM: 1.21 (+0.06), FMI: 48.88 (+0.17), GILD: 101.90 (+1.10), GERN: 3.03 (unch), SHPG: 239.82 (+6.11), SRPT: 12.76 (+0.11)
Hepatitis B Drug from Arrowhead Research Corp. Placed on Partial Clinical Hold by FDA; CBCD Reviews the Report
PRWeb - Thu Jan 15, 11:03PM CST
"Infected with the hepatitis B virus (HBV)? The CBCD recommends taking Novirin or Gene-Eden-VIR." - Greg Bennett, CBCD
ARWR: 6.77 (+0.21)
Insider Trading Alert - CFX, ARWR And FMI Traded By Insiders
at The Street - Thu Jan 15, 9:30AM CST
Stocks with insider trader activity include CFX, ARWR and FMI
FMI: 48.88 (+0.17), ARWR: 6.77 (+0.21), CFX: 52.02 (+3.84)
Robbins Arroyo LLP Is Investigating the Officers and Directors of Arrowhead Research Corporation (ARWR) on Behalf of Shareholders
PR Newswire - Wed Jan 14, 1:58PM CST
Shareholder rights law firm Robbins Arroyo LLP is investigating whether certain officers and directors of Arrowhead Research Corporation (NASDAQGS: ARWR) breached their fiduciary duties to shareholders. Arrowhead is a biopharmaceutical company that develops targeted RNAi therapeutics in the United States.
ARWR: 6.77 (+0.21)
Critical Alerts For Juno Therapeutics Inc, Arrowhead Research, Bitauto Holdings, Intrexon and Inovio Pharmaceuticals Released By InvestorsObserver
PR Newswire - Wed Jan 14, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for JUNO, ARWR, BITA, XON and INO.
INO: 6.80 (-0.15), ARWR: 6.77 (+0.21), XON: 39.30 (+1.05), JUNO: 40.52 (+0.18), BITA: 62.95 (+2.85)
Nasdaq stocks posting largest percentage decreases
AP - Tue Jan 13, 5:15PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
DISCK: 30.32 (+0.80), ARWR: 6.77 (+0.21), AFMD: 5.70 (-0.25), TFM: 37.14 (+0.07), SRPT: 12.76 (+0.11), DISCB: 31.64 (+0.64), DISCA: 31.45 (+1.11), POZN: 6.95 (+0.15), PEIX: 9.82 (+0.15), GFN: 9.20 (+0.25), HLSS: 16.15 (-0.14), DXPE: 46.57 (+1.42), OBAS: 6.25 (-0.05)
Why Shares of Arrowhead Research Corp Imploded Today
Alex Planes, The Motley Fool - Motley Fool - Mon Jan 12, 1:09PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Arrowhead Research , a small...
ARWR: 6.77 (+0.21)
Today's Review on Biotech Equities - Vertex Pharma, Alexion Pharma, Arrowhead Research, Medivation, and Incyte
PR Newswire - Tue Feb 10, 8:10AM CST
Editor Note: For more information about this release, please scroll to bottom.
MDVN: 104.71 (+0.67), VRTX: 113.66 (+4.03), ARWR: 6.77 (+0.21), INCY: 75.94 (+0.28), ALXN: 182.29 (+6.02)
Arrowhead Research Corporation's (ARWR) CEO Chris Anzalone on Q1 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Feb 09, 9:59PM CST
ARWR: 6.77 (+0.21)
Arrowhead Research (ARWR) Q1 2015 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Mon Feb 09, 3:25PM CST
ARWR: 6.77 (+0.21)
Arrowhead Research reports 1Q loss
Automated Insights - Mon Feb 09, 3:12PM CST
PASADENA, Calif. (AP) _ Arrowhead Research Corp. (ARWR) on Monday reported a loss of $22.6 million in its fiscal first quarter.
ARWR: 6.77 (+0.21)
Arrowhead Research Corporation misses by $0.07
Seeking Alpha - at Seeking Alpha - Mon Feb 09, 3:03PM CST
ARWR: 6.77 (+0.21)
Arrowhead Reports Fiscal 2015 First Quarter Financial Results
Business Wire - Mon Feb 09, 3:01PM CST
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced financial results for its fiscal 2015 first quarter ended December 31, 2014. The company is hosting a conference call at 4:30 p.m. EST to discuss results.
ARWR: 6.77 (+0.21)
Earnings Peek: Arrowhead Research Corporation's Focus Is On The Clinical Hold
Clinically Sound Investor - at Seeking Alpha - Wed Feb 04, 8:42AM CST
ARWR: 6.77 (+0.21)
Why Arrowhead Research Corp. Shares Plunged 14% in January
Sean Williams, The Motley Fool - Motley Fool - Mon Feb 02, 4:40PM CST
ARWR data by YCharts What: Shares of Arrowhead Research , a clinical-stage biopharmaceutical company focused on treating serious diseases through RNA-therapeutics, plunged 14% in January based on data from S&P Capital IQ following an...
ARWR: 6.77 (+0.21)
Arrowhead Research reports February 9
Seeking Alpha - at Seeking Alpha - Mon Feb 02, 3:15PM CST
ARWR: 6.77 (+0.21)
Arrowhead to Report Fiscal 2015 First Quarter Financial Results
Business Wire - Mon Feb 02, 3:01PM CST
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it will report its financial results for the fiscal 2015 first quarter ended December 31, 2014, on Monday, February 9, 2015, at 4:30 p.m. EST. To participate in the conference call, please dial 855-215-6159 (toll free from the US) or 315-625-6887 (for international callers) and enter Conference ID 76024600. Investors may also access a live audio webcast of this conference call on the Company's website at http://ir.arrowheadresearch.com/events.cfm.
ARWR: 6.77 (+0.21)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Jan 22, 8:15AM CST
ARWR: 6.77 (+0.21), BBRY: 10.09 (+0.23), NADL: 2.10 (-0.02), FXCM: 2.21 (-0.01), CYN: 90.32 (+0.49), PBR: 6.98 (+0.44), XLNX: 41.51 (+0.51), NERV: 4.68 (+0.09), FWM: 5.55 (+0.08), CYTR: 2.96 (+0.23), FFIV: 116.64 (+1.37), LOGI: 14.86 (-0.02), LE: 35.84 (+0.19), SNDK: 82.81 (+0.51)
Downgrade Alert for Arrowhead Research (ARWR)
Comtex SmarTrend(R) - Thu Jan 22, 7:17AM CST
Arrowhead Research (NASDAQ:ARWR) was downgraded from Buy to Hold at Deutsche Bank today. The stock closed yesterday at $6.76 on volume of 1.8 million shares, below average daily volume of 3.2 million. There is potential upside of 162.6% for shares of Arrowhead Research based on a current price of $6.76 and an average consensus analyst price target of $17.75. The stock should hit resistance at its 200-day moving average (MA) of $10.80, as well as support at its 50-day MA of $6.31.
ARWR: 6.77 (+0.21)
Seeking Alpha's Biotech Weekly: Roche Takes Control, Shire's A Buyer, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Jan 16, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
ZIOP: 9.64 (-0.35), ARWR: 6.77 (+0.21), XON: 39.30 (+1.05), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), MNKD: 7.00 (+0.02), RGDO: 1.17 (+0.02), HUM: 152.67 (-1.06), ETRM: 1.21 (+0.06), FMI: 48.88 (+0.17), GILD: 101.90 (+1.10), GERN: 3.03 (unch), SHPG: 239.82 (+6.11), SRPT: 12.76 (+0.11)
Hepatitis B Drug from Arrowhead Research Corp. Placed on Partial Clinical Hold by FDA; CBCD Reviews the Report
PRWeb - Thu Jan 15, 11:03PM CST
"Infected with the hepatitis B virus (HBV)? The CBCD recommends taking Novirin or Gene-Eden-VIR." - Greg Bennett, CBCD
ARWR: 6.77 (+0.21)
Insider Trading Alert - CFX, ARWR And FMI Traded By Insiders
at The Street - Thu Jan 15, 9:30AM CST
Stocks with insider trader activity include CFX, ARWR and FMI
FMI: 48.88 (+0.17), ARWR: 6.77 (+0.21), CFX: 52.02 (+3.84)
Robbins Arroyo LLP Is Investigating the Officers and Directors of Arrowhead Research Corporation (ARWR) on Behalf of Shareholders
PR Newswire - Wed Jan 14, 1:58PM CST
Shareholder rights law firm Robbins Arroyo LLP is investigating whether certain officers and directors of Arrowhead Research Corporation (NASDAQGS: ARWR) breached their fiduciary duties to shareholders. Arrowhead is a biopharmaceutical company that develops targeted RNAi therapeutics in the United States.
ARWR: 6.77 (+0.21)
Critical Alerts For Juno Therapeutics Inc, Arrowhead Research, Bitauto Holdings, Intrexon and Inovio Pharmaceuticals Released By InvestorsObserver
PR Newswire - Wed Jan 14, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for JUNO, ARWR, BITA, XON and INO.
INO: 6.80 (-0.15), ARWR: 6.77 (+0.21), XON: 39.30 (+1.05), JUNO: 40.52 (+0.18), BITA: 62.95 (+2.85)
Nasdaq stocks posting largest percentage decreases
AP - Tue Jan 13, 5:15PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
DISCK: 30.32 (+0.80), ARWR: 6.77 (+0.21), AFMD: 5.70 (-0.25), TFM: 37.14 (+0.07), SRPT: 12.76 (+0.11), DISCB: 31.64 (+0.64), DISCA: 31.45 (+1.11), POZN: 6.95 (+0.15), PEIX: 9.82 (+0.15), GFN: 9.20 (+0.25), HLSS: 16.15 (-0.14), DXPE: 46.57 (+1.42), OBAS: 6.25 (-0.05)
Why Shares of Arrowhead Research Corp Imploded Today
Alex Planes, The Motley Fool - Motley Fool - Mon Jan 12, 1:09PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Arrowhead Research , a small...
ARWR: 6.77 (+0.21)
